Compare Citius Pharmaceuticals Inc (CTXR) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Snap On Incorporated — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Snap On Incorporated trades at $360.37 (market cap $18.56B). The key difference: Snap On Incorporated is far larger — about 1362.7× Citius Pharmaceuticals Inc's market cap, and Snap On Incorporated pays a 2.72% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Snap On Incorporated for 37 Days on average.
| CTXR | SNA | |
|---|---|---|
Market Cap | $13.62M | $18.56B |
Volume | 132,438 | 401,326 |
Sector | Health | Industrials |
52-Week High | $1.82 | $419.31 |
52-Week Low | $0.48 | $327.33 |
Typical Hold Time | 17 Days | 37 Days |
Enterprise Value | $3.79M | $18.20B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
Snap-On Incorporated (SNA) trades at $360.37, up 0.13% on the day, with a bearish technical outlook but strong fundamentals. The stock shows robust profitability with a 19.6% net income margin and 17.58% ROE, supported by consistent earnings beats in recent quarters. Analyst consensus is bullish with a $449 price target, though technical indicators signal selling pressure near key resistance at $361.
SNA presents a compelling investment case driven by solid earnings growth and expanding margins, but faces near-term technical headwinds and valuation risks. The stock's premium P/E of 18.31 may limit upside if growth moderates, while institutional activity shows mixed positioning. Investors should weigh strong cash flow against competitive pressures in the tools sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
